EAGLE PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • October 21st, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of April 11, 2013, by and among Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series A Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series A Holders”), the holders of the Company’s Series B Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series B Holders”), the holders of the Company’s Series B-1 Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series B-1 Holders”), the holders of the Company’s Series C Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series C Holders” and, collectively with the Series A Holders, the Series B Holders and the Series B-1 Holders, the “Investors”) and Scott L. Tarriff (the “Key Employee”).
